Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter Phase II Study of Rituximab plus Bendamustine in Extranodal Marginal Zone B-cell Lymphoma of MALT
2008-007725-39Phase 2Completed
- Sponsor
- Fundación GEL
- Start
- Mar 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab and bendamustine in marginal zone B-cell lymphoma (MZL) and extranodal marginal zone B-cell lymphoma (EMZL), sponsored by Fundación GEL. Primary endpoint: Event-free survival (EFS). Started Mar 2009; status: completed.
02
Drugs
rituximabbendamustine
03
Conditions
marginal zone B-cell lymphoma (MZL)extranodal marginal zone B-cell lymphoma (EMZL)
Beyond the preview
Go deeper on 2008-007725-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007725-39.